NEJM This Week — September 4, 2025
NEJM This Week
00:00
Intro
This chapter discusses the Phase II trial of Meritibard-Cafra, a new obesity treatment that combines GLP-1 receptor agonism and GIP receptor antagonism. Findings indicate significant weight loss among participants, with a focus on the differentiation of effects in those with and without type 2 diabetes.
Transcript
Play full episode
